NANOGAP Therapeutics relaunched as ARJUNA Therapeutics
Santiago de Compostela, Spain and St Anselmo, California, USA
emerging biotechnology leader developing an entirely novel class of small molecules,
Therapeutic Molecular Clusters (TMC), for the treatment of aggressive cancers and other
diseases with no effective treatments. Arjuna has a unique proprietary platform of new
medicines to address the most significant unmet needs in cancer medicine, including all
KRas-mutation driven cancers, glioblastoma, metastatic cancers, and triple-negative breast
cancer. The more aggressive the cancer, the more effective our treatments.
Our proprietary TMC platform was developed by our scientific co-founders Professor Arturo
López Quintela Ph.D. and Fernando Dominguez MD Ph.D. TMCs have unique therapeutic
mechanisms of action, excellent tissue penetration and low toxicity. We have validated
Therapeutic Molecular Clusters in our internal preclinical work for several indications, and
we are working towards starting human proof of concept studies for our lead drug in 2021.
The company is advancing a robust pipeline of compounds to remove the fear of a cancer
diagnosis for every patient and every family. Our lead molecule Ag5 is the first TMC,
targeting the hardest to treat cancers, in a novel-biomarker defined population, using a
catalytic mechanism of action to target cancer cells generating high levels of reactive oxygen species. The first disease indications for Ag5 are KRas-mutant cancers of all histological types and glioblastoma. Our second molecule in preclinical studies, Ag3, has the potential to augment all current radiotherapy, chemotherapy, and immunotherapy protocols. Arjuna was awarded the most innovative new oncology company in the inaugural BioTarget 2019 contest. More information on Arjuna can be found at: http://www.arjunatherapeutics.com.